GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Medexus Pharmaceuticals Inc (TSX:MDP) » Definitions » Investments And Advances

Medexus Pharmaceuticals (TSX:MDP) Investments And Advances : C$0.0 Mil (As of Dec. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Medexus Pharmaceuticals Investments And Advances?

Medexus Pharmaceuticals's Investments And Advances for the quarter that ended in Dec. 2024 was C$0.0 Mil.


Medexus Pharmaceuticals Investments And Advances Historical Data

The historical data trend for Medexus Pharmaceuticals's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medexus Pharmaceuticals Investments And Advances Chart

Medexus Pharmaceuticals Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Investments And Advances
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Medexus Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Medexus Pharmaceuticals Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.


Medexus Pharmaceuticals Business Description

Traded in Other Exchanges
Address
10 King Street East, Suite 600, Toronto, ON, CAN, M5C 1C3
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology.
Executives
Brendon Buschman Senior Officer
Mike Mueller Director
Benoit Gravel Director
Stephen William Nelson Director
Kenneth D'entremont Director, Senior Officer
Marcel Pascal Konrad Senior Officer
Brian Peters Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Roland Boivin Senior Officer
Michael Pine Senior Officer
Glenn Tate Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Richard Labelle Senior Officer
Benoît Hébert Senior Officer